Galena Biopharma closes enrollment in Phase II trial of GALE-401
The MPNs include essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). A total of 18 patients have been enrolled in this open-label, single-arm, multicenter Phase II